Peptides Education

SS-31 (Elamipretide) and Mitochondrial Cardiolipin: Respiratory Supercomplexes and the SERCA Trial | QSC

/Posted by / 46
TIER 2 RESEARCH OVERVIEW — MITOCHONDRIAL BIOLOGY
Elamipretide | Cardiolipin | Respiratory Supercomplexes | SERCA Phase 2

SS-31 (elamipretide) represents a mechanistically novel approach to mitochondrial medicine. Rather than scavenging reactive oxygen species after they are produced — the approach of CoQ10, MitoQ, and most mitochondria-targeted antioxidants — SS-31 prevents their overproduction at the source by stabilising cardiolipin and maintaining the physical integrity of the respiratory supercomplex. Understanding why this matters requires understanding what cardiolipin does, what happens when it is damaged, and why respiratory supercomplexes are the fundamental unit of mitochondrial efficiency.

Cardiolipin — The Structural Lipid of the Inner Mitochondrial Membrane

Cardiolipin (CL) is a unique dimeric phospholipid — two phosphatidic acids linked by a glycerol backbone — found almost exclusively in the inner mitochondrial membrane (IMM) and in bacterial membranes. In the IMM, it constitutes approximately 20% of total phospholipid content. Its structural uniqueness (four fatty acid tails, two phosphate headgroups, net charge −2 at physiological pH) makes it ideally suited for three critical IMM functions:

Function How cardiolipin enables it Consequence of CL damage
Respiratory supercomplex assembly CL stabilises protein-protein contacts between Complex I, III, and IV — enables supercomplexes (I₁III₂IV₁) Supercomplex dissociation → reduced electron transfer efficiency → increased electron leak → ROS
Cytochrome c anchoring Electrostatic interaction with cyt c on IMM surface — maintains cyt c in ETC position Cyt c released → peroxidase activity → CL peroxidation → apoptosis cascade
Proton gradient maintenance CL headgroups buffer protons at the IMM surface — maintains local H+ concentration for ATP synthase Dissipated proton gradient → reduced ATP synthesis efficiency

Why cardiolipin oxidation creates a vicious cycle

Damaged Complex I and III produce superoxide. Superoxide → H2O2 → hydroxyl radical (via Fenton). Cytochrome c (loosely bound to CL) acts as a cardiolipin-specific peroxidase when CL is peroxidised — converting more CL to oxidised forms. Oxidised CL loses structural function → more supercomplex dissociation → more electron leak → more superoxide. SS-31 interrupts this cycle by preventing the initial CL peroxidation step.

⚙️

SS-31 Mechanism — Cardiolipin Stabilisation

SS-31 (D-Arg-2’6′-Dmt-Lys-Phe-NH₂) is a tetrapeptide with a specifically engineered structure for IMM targeting and CL interaction:

Mitochondrial targeting — electrostatic accumulation

The alternating aromatic/cationic residue pattern (+2 net charge) is attracted to the large negative membrane potential of the IMM (−180 mV). SS-31 accumulates 1000-fold at the IMM relative to cytosol — concentrating where it is needed without requiring active transport. This passive electrostatic targeting is fundamentally different from triphenylphosphonium-conjugated compounds (MitoQ) which accumulate at the IMM but may have off-target effects.

Cardiolipin binding — the 2’6′-Dmt interaction

2’6′-dimethyltyrosine (Dmt) is the modified aromatic residue critical for CL binding. The methyl groups on the tyrosine ring increase hydrophobicity and CL affinity. SS-31/CL interaction is non-covalent — it does not permanently modify CL but sterically prevents cytochrome c from using CL as a peroxidase substrate. This is a protection mechanism, not a covalent adduct.

Respiratory supercomplex stabilisation

By preserving CL structural integrity, SS-31 maintains the protein-protein contacts within the I₁III₂IV₁ respirome supercomplex. Preserved supercomplexes channel electrons more efficiently from NADH → Complex I → CoQ → Complex III → cytochrome c → Complex IV → O₂ — minimising the electron residence time on CoQ and the probability of electron leak to oxygen (superoxide formation).

Research Evidence — From Isolated Mitochondria to Human Phase 2

Study Model Key result
Szeto et al. 2014 (JASN) Aged mouse kidney SS-31 restored tubular mitochondrial cristae morphology (TEM), reduced mitochondrial ROS, improved creatinine clearance
Chatfield et al. 2017 (Sci Trans Med) Aged mouse exercise Single SS-31 injection restored mitochondrial respiration (State 3) and exercise capacity within 1 hour — before any gene expression changes
Bhatt et al. 2020 (Circulation) Heart failure with preserved EF (HFpEF) mouse SS-31 improved diastolic function and exercise tolerance — cardiac supercomplex restoration confirmed
SERCA Phase 2 2020 (Clinicaltrials) HFpEF patients, IV infusion Improved LVESV, LVEF vs placebo — first human IV mitochondrial peptide trial with cardiac function improvement
Dai et al. 2014 (JMCC) Cardiac IR model SS-31 reduced infarct size, maintained cytochrome c in ETC position, reduced MPTP opening

Why the Chatfield 2017 result matters

Chatfield et al. showed SS-31 improved mitochondrial respiration and exercise capacity in aged mice within ONE HOUR of a single injection — faster than any gene expression change is possible. This rapid onset confirms the mechanism is physical (CL stabilisation / supercomplex integrity) rather than transcriptional. It also establishes the experimental framework for acute SS-31 protocols: measure before injection, re-measure 1-4 hours post — capturing the direct biophysical effect without chronic adaptive changes.

❓

Frequently Asked Questions

What makes SS-31 different from other mitochondria-targeted antioxidants?

Most mitochondria-targeted antioxidants (CoQ10, MitoQ, SkQ1) scavenge superoxide or H2O2 after they are produced. SS-31 prevents overproduction at the source by stabilising cardiolipin and maintaining respiratory supercomplex assembly — reducing electron leak before ROS are generated. It also has the CD36-independent cardiac targeting that MitoQ lacks.

What is the SERCA Phase 2 trial?

SERCA (Elamipretide — Chronic Therapy for Heart Failure) was a Phase 2 trial in HFpEF patients. IV elamipretide reduced left ventricular end-systolic volume and improved ejection fraction vs placebo — the first demonstration that a mitochondria-targeted peptide improves cardiac function in human heart failure.

Why does SS-31 work within one hour in aged mice?

The Chatfield 2017 result shows SS-31 restores mitochondrial respiration and exercise capacity within 1 hour of injection — faster than transcriptional changes. This confirms the mechanism is biophysical: SS-31 accumulates at the IMM, binds CL, prevents cytochrome c peroxidase activity, and restores respiratory supercomplex integrity — all within minutes.

What are the best research models for SS-31?

Isolated mitochondria (State 3/4 respiration, RCR, complex activity); aged mouse in vivo (grip strength, treadmill, Seahorse respiration on isolated muscle mitochondria); cardiac ischaemia-reperfusion (LAD ligation); HFpEF model (pressure overload or high fat diet); and cardiolipin peroxidation assay (HPLC-MS of CL molecular species).

Research Use Only: All QSC compounds are sold strictly for laboratory research purposes. Not for human use. Not approved by the FDA or equivalent regulatory bodies for human administration.

Comments are closed

Peptides
Blends
Tablets
Search
Contact